

Ghana has stopped mass drug administration (MDA) for lymphatic filariasis in 90% of endemic districts in the country following interruption of transmission of the causative parasite in 103 districts as of FY21 (October 2020 – September 2021). Prevalence of infection has been reduced significantly in the remaining 11 districts due to ongoing MDA.

Ghana was validated by the World Health Organization as having eliminated trachoma as a public health problem in 2018—the first nation in sub-Saharan Africa to achieve this.

Ghana has started implementing two rounds of OV MDA annually since 2018. The new treatment strategy targets 76 health districts and aimed to accelerate onchocerciasis elimination by 2030.

Ghana was the first Act West countries to form a schistosomiasis expert committee in 2021. As a result of multiple rounds of high coverage MDA, Ghana will conduct its second schistosomiasis/soil-transmitted helminthiasis (SCH/STH) impact assessment (the first re-assessment survey was in 2015) in nine districts in 2022. Ghana was one of four countries in West Africa selected by the Task Force for Global Health to conduct a SCH Oversampling survey in 2022. The data from both of these surveys will be considered at a data review meeting in 2022 to re-assess its treatment strategy going forward.
Standard Disease-Specific Indicators as of FY20
FY20 is October 2019 through September 2020

of ever-endemic districts have stopped mass drug administration (MDA) as of FY20
(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))
of ever-endemic districts in post-surveillance phase as of FY20
(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))
of persons no longer at risk as of FY20 among those who were ever at risk
Trachoma eliminated (validated by WHO) in 2018 under END in Africa Program.

of ever endemic districts have been treated at least once as of FY20

of ever endemic districts have been treated at least once as of FY20
